<DOC>
	<DOCNO>NCT02527096</DOCNO>
	<brief_summary>The principal objective evaluate antiviral efficacy 48 week treatment two-drugs combination dolutegravir ( Tivicay® ) lamivudine ( TEpivir® ) HIV-1 infected patient virologically suppress triple HAART .</brief_summary>
	<brief_title>A Trial Evaluating Maintenance Therapy With Lamivudine ( Epivir® ) Dolutegravir ( Tivicay® ) Human Immunodeficiency Virus 1 ( HIV-1 ) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy ( HAART ) ( ANRS 167 Lamidol )</brief_title>
	<detailed_description>Secondary objective : The follow parameter evaluate : - Evolution CD4 cell CD8 cell - Tolerance treatment - Emergence resistance mutation time virological failure - HIV viral load measure ultrasensitive assay ( threshold 1 copy/mL ) Day 0 , Week 8 , Week 32 Week 56 - Influence total DNA Day 0 occurrence virological failure blip - Plasma level dolutegravir ( Tivicay® ) lamivudine participant virological failure - Adherence treatment - Quality life - Medico-economic aspect - Dolutegravir ( Tivicay® ) Nucleosidic Reverse Transcriptase Inhibitors ( NRTIs ) level , HIV viral load semen subgroup 20 participant . Methodology : Pilot trial , multicentric , national , prospective , randomized comparative .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 infect patient Age ≥ 18 year CD4 cell count nadir &gt; 200/mm3 Genotype preHAART interpret last version ANRS AC11 resistance group 's algorithm present : major mutation protease among : D30N , V32I , M46I/L , I47A/V , G48V , I50L/V , 154M/L , L76V , V82A/F/T/S , I84V , N88D/S , L90M , mutation RT ( except mutation A98S patient infect virus subtype C ) , mutation integrase ( genotype available ) , Firstline treatment suppressive triple HAART ( 2 NRTI + either 1 PI/r , 1 NNRTI 1 INI ) . The initial treatment may change maximum two time toxicity ( change Epivir / Ziagen Kivexa , consider change treatment ) . However , treatment unchanged last 6 month Plasma HIV RNA ≤ 50 copies/mL ≥ 2 year least 2 viral load determination per year . Blips ( HIV viral load 50 200 copies/mL ≤ 50 copies/mL control sample ) allow except last 6 month . The total number blip must exceed 3 last 2 year Negative Hepatitis Bs Antigen Effective contraception woman childbearing potential Informed consent form sign patient investigator Patient enrol beneficiary Social Security programme ( State Medical Aid ( `` Aide Médicale d'Etat '' AME France ) Social Security programme ) HIV2 infection Positive HBc Ac isolate Hepatitis B Virus ( HBV ) coinfected patient ( positive Hepatitis Bs Ag inclusion ) Chronic hepatitis C currently treat need therapy next 12 month History HIVassociated neurocognitive disorder Current pregnancy breastfeed No effective contraception woman childbearing Previous treatment chemotherapy ( except bleomycin Kaposi disease 's treatment ) immunotherapy Grade &gt; 2 abnormality usual biological parameter ( liver function test , blood cell count ) ALT ( Alanine Aminotransferase ) ≥ 5 x upper limit normal value ( ULN ) AST ( Aspartate Aminotransferase ) ≥ 3 x ULN bilirubinemia ≥ 1.5 x ULN ( 35 % direct bilirubinemia ) Unstable liver disease ( ascitis , encephalopathy , coagulopathy , hypoalbuminemia , oesophageal gastric varix persistent jaundice ) Known biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Creatininemia clearance 50 mL/min ( CockroftGault method ) History presence allergy trial drug component Severe hepatic insufficiency ( Child Pugh Class C ) Patients participate another clinical trial include exclusion period still force screen phase Patients `` sauvegarde de justice '' ( judicial protection due temporarily slightly diminish mental physical faculty ) legal guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>dolutegravir ( Tivicay® )</keyword>
	<keyword>lamivudine ( Epivir® )</keyword>
	<keyword>HIV-1</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>